Rizatriptan, a novel 5-HT(1B/1D) agonist for migraine: Single- and multiple-dose tolerability and pharmacokinetics in healthy subjects

Journal of Clinical Pharmacology

Volumn 40, Issue 1, 2000, Pages 74-83

  Goldberg, M R ^a   Lee, Y ^a   Vyas, K P ^a   Slaughter, D E ^a   Panebianco, D ^a   Ermlich, S J ^a   Shadle, C R ^a   Brucker, M J ^a   McLoughlin, D A ^a   Olah, T V ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RIZATRIPTAN;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG HALF LIFE; FEMALE; HEADACHE; HUMAN; INCIDENCE; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; MIGRAINE; SOMNOLENCE; STATISTICAL ANALYSIS; SYNCOPE; UNITED STATES; VERTIGO;

EID: 0033710106     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022008595     Document Type: Article

References (11)

1. Prevalence of migraine headache in the United States: Relation to age, income, race and other sociodemographic factors
2. In vitro pharmacological profile of the novel 5-HT(1D) receptor agonist, MK-462
3. Dose-finding studies of rizatriptan (MK-462) in the acute treatment of migraine
4. The clinical pharmacology, pharmacokinetics, and metabolism of sumatriptan
5. In vivo and in vitro metabolism of MK-462, a potent and selective agonist of the 5-HT(1D) receptor
6. Quantitation of the 5HTID agonists MK-462 and sumatriptan in plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry
7. Placebo-controlled, double-blind study of rizatriptan in multiple attacks of acute migraine
8. Rizatriptan (MK-0462) for the acute treatment of migraine and migraine recurrence
9. Rizatriptan vs sumatriptan in the acute treatment of migraine: A placebo-controlled, dose-ranging study
10. Initial human experience with MK-462 (rizatriptan): A novel 5-HT-1D agonist